Hoffmann-La Roche

189 results found.

Schizophrenia Clinical Trial using bitopertin [RO4917838]; Placebo

Hoffmann-La Roche - Recruiting 18 years or older.
- A Phase III, Multi-center, Randomized, 24 Week, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate Efficacy and Safety of RO4917838 in Stable Patients With Persistent, Predominant Negative Symptoms of Schizophrenia Treated With Antipsychotics Followed by a 28 Week, Double-blind Treatment Period..
bitopertin [RO4917838]; Placebo

Lymphocytic Leukemia, Chronic Clinical Trial using rituximab [MabThera]; fludarabine; cyclophosphamide

Hoffmann-La Roche - Recruiting 18 years to 70 years.
- Prospective Study of Efficacy and Safety of RFC (Rituximab, Fludarabine, Cyclophosphamide) Regimen as a First-Line Therapy in Patients With B-Cell Chronic Lymphocytic Leukemia and Favorable Somatic Status.
rituximab [MabThera]; fludarabine; cyclophosphamide

Hepatitis C, Chronic Clinical Trial

Hoffmann-La Roche - Recruiting 18 years or older.
- A Prospective, Observational, Multicenter Non-interventional Trial Examining Efficacy of Combination Therapy With PEGASYSr Plus COPEGUSr in Patients With Chronic Hepatitis C, Genotype 2, 3, 1 or 4, Undergoing an Opioid Maintenance-Therapy With Special Focus on Patient Compliance and Quality of Life.

Hepatitis B, Chronic Clinical Trial using peginterferon alfa-2a [Pegasys]

Hoffmann-La Roche - Recruiting 3 years to 17 years.
- A Phase IIIb Parallel Group, Open Label Study of Pegylated Interferon Alfa-2a Monotherapy (PEG-IFN, Ro 25-8310) Compared to Untreated Control in Children With HBeAg Positive Chronic Hepatitis B.
peginterferon alfa-2a [Pegasys]

Colorectal Cancer Clinical Trial using bevacizumab [Avastin]; XELOX; mFOLFOX6; FOLFIRI

Hoffmann-La Roche - Recruiting 18 years or older.
- An Australian Translational Study to Evaluate the Prognostic Role of Inflammatory Markers in Patients With Metastatic Colorectal Cancer Treated With Bevacizumab (Avastin) [ASCENT].
bevacizumab [Avastin]; XELOX; mFOLFOX6; FOLFIRI

Influenza Clinical Trial using oseltamivir

Hoffmann-La Roche - Recruiting 1 year or older.
- A Double-blind, Randomized, Stratified Multi-center Trial Evaluating Conventional and Double Dose Oseltamivir in the Treatment of Immunocompromised Patients With Influenza.
oseltamivir

Macular Degeneration Clinical Trial using RO6867461

Hoffmann-La Roche - Recruiting 50 years or older.
- A Multiple-Center, Non-Randomized, Open-Label, Single-Ascending-Dose, Parallel Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO6867461 Following Intravitreal Administration in Patients With Wet Age-Related Macular Degeneration..
RO6867461

Renal Cell Carcinoma Clinical Trial using MPDL3280A; bevacizumab [Avastin]; sunitinib

Hoffmann-La Roche - Recruiting 18 years or older.
- A PHASE II, RANDOMIZED STUDY OF MPDL3280A ADMINISTERED AS MONOTHERAPY OR IN COMBINATION WITH BEVACIZUMAB VERSUS SUNITINIB IN PATIENTS WITH UNTREATED ADVANCED RENAL CELL CARCINOMA.
MPDL3280A; bevacizumab [Avastin]; sunitinib

Asthma Clinical Trial using Lebrikizumab; Placebo

Hoffmann-La Roche - Recruiting 12 years to 75 years.
- A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, MULTICENTER TRIAL TO ASSESS THE ORAL CORTICOSTEROID-SPARING EFFECT OF LEBRIKIZUMAB IN PATIENTS WITH SEVERE CORTICOSTEROID-DEPENDENT ASTHMA.
Lebrikizumab; Placebo

Neoplasms Clinical Trial using RO6895882

Hoffmann-La Roche - Recruiting 18 years or older.
- AN OPEN-LABEL, MULTI-CENTER, DOSE-ESCALATION, PHASE I STUDY WITH AN EXPANSION PHASE, TO EVALUATE SAFETY, PHARMACOKINETICS AND THERAPEUTIC ACTIVITY OF RO6895882, AN IMMUNOCYTOKINE, CONSISTING OF A VARIANT OF INTERLEUKIN-2 (IL-2v) TARGETING CARCINOEMBRYONIC ANTIGEN (CEA) ADMINISTERED INTRAVENOUSLY, IN PATIENTS WITH ADVANCED AND/OR METASTATIC SOLID TUMORS.
RO6895882

Schizophrenia Clinical Trial using bitopertin [RO4917838]; Placebo

Hoffmann-La Roche - Recruiting 18 years or older.
- Phase III, Multi-center, Randomized, 12-week, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of RO4917838 in Patients With Sub-optimally Controlled Symptoms of Schizophrenia Treated With Antipsychotics Followed by a 40-week Double-blind, Parallel-group, Placebo-controlled Treatment Period..
bitopertin [RO4917838]; Placebo

Non-Small Cell Lung Cancer Clinical Trial using erlotinib [Tarceva]; gemcitabine; cisplatin

Hoffmann-La Roche - Recruiting 18 years or older.
- A Multiple Center, Open-label, Randomized Phase III Study to Evaluate the Efficacy and Safety of Erlotinib (Tarceva) Versus Gemcitabine/Cisplatin as the First-line Treatment for Stage IIIB/IV NSCLC Patients With Mutations in the Tyrosine Kinase Domain of Epidermal Growth Factor Receptor (EGFR) in Their Tumor.
erlotinib [Tarceva]; gemcitabine; cisplatin

Neoplasms Clinical Trial using RO5503781

Hoffmann-La Roche - Recruiting 18 years or older.
- A Multi-center, Open Label, First in Human Phase I Dose Escalation Study of Single Agent RO5503781, a Small Molecule MDM2 Antagonist, Administered Orally in Patients With Advanced Malignancies, Except Leukemia.
RO5503781

Rheumatoid Arthritis Clinical Trial

Hoffmann-La Roche - Recruiting 18 years or older.
- Non-interventional Local Study to Describe the Safety, Tolerability and Efficacy of Tocilizumab in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Current Non-biologic DMARD.

Rheumatoid Arthritis Clinical Trial

Hoffmann-La Roche - Recruiting 18 years or older.
- A Multi-national, Multi-center Non-interventional Study in Rheumatoid Arthritis (RA) Patients Treated With Tocilizumab.

Anemia Clinical Trial

Hoffmann-La Roche - Recruiting 18 years or older.
- Non-interventional Study to Assess the Efficacy of Mircera for Renal Anemia Correction in Dialysis Patients in Everyday Clinical Practice in Poland..

Colorectal Cancer Clinical Trial

Hoffmann-La Roche - Recruiting 18 years or older.
- Program for Assessment of Capecitabine (Xeloda) Based First-line Therapies in Metastatic Colorectal Cancer (AXEL Study).

Breast Cancer Clinical Trial

Hoffmann-La Roche - Recruiting 18 years or older.
- Program for Assessment of Capecitabine (Xeloda) Plus Docetaxel First-line Therapies in HER2-negative Metastatic Breast Cancer (XEBRA Study).

Ovarian Cancer, Peritoneal Neoplasms Clinical Trial

Hoffmann-La Roche - Recruiting 18 years or older.
- A Non-interventional Trial With Avastin as Front-line Treatment for Ovarian Cancer.

Rheumatoid Arthritis Clinical Trial

Hoffmann-La Roche - Recruiting 18 years or older.
- A Multi-Center Observational Study on the Use of Biologic Drugs as Monotherapy or Combination With DMARDs in Patients With Rheumatoid Arthritis in Italian Clinical Practice.

Non-Small Cell Lung Cancer Clinical Trial using RO5424802

Hoffmann-La Roche - Recruiting 18 years or older.
- A Phase I/II Study of the ALK Inhibitor CH5424802/ RO5424802 in Patients With ALK-Rearranged Non-Small Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib.
RO5424802

Malignant Melanoma Clinical Trial using Zelboraf

Hoffmann-La Roche - Recruiting 18 years or older.
- An Open-Label, Single-Arm, Multicenter Study To Assess The Safety Of Vemurafenib In Patients With Braf V600 Mutation Positive Metastatic Melanoma In South Africa..
Zelboraf

Breast Cancer Clinical Trial using trastuzumab [Herceptin]; Chemotherapy

Hoffmann-La Roche - Recruiting 18 years or older.
- An Open Label, Randomised Phase II Study Assessing Quality of Life Associated With Subcutaneous Trastuzumab Injected Into the Thigh or Upper Arm in Patients With HER2-positive Early Breast Cancer.
trastuzumab [Herceptin]; Chemotherapy

Lymphoma, Non Hodgkin Clinical Trial using rituximab [MabThera/Rituxan]

Hoffmann-La Roche - Recruiting 18 years to 80 years.
- OPEN LABEL, SINGLE-ARM, PHASE IIIb CLINICAL TRIAL TO EVALUATE THE SAFETY OF SWITCHING FROM INTRAVENOUS RITUXIMAB TO SUBCUTANEOUS RITUXIMAB DURING FIRST LINE TREATMENT FOR CD20+ NON-HODGKIN'S FOLLICULAR LYMPHOMA AND DIFFUSE LARGE B-CELL LYMPHOMA..
rituximab [MabThera/Rituxan]

Healthy Volunteer Clinical Trial using RO6864018

Hoffmann-La Roche - Recruiting 21 years to 65 years.
- A PHASE I, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SINGLE ASCENDING DOSE STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF RO6864018 FOLLOWING ORAL ADMINISTRATION IN ASIAN HEALTHY SUBJECTS.
RO6864018

Alzheimer Disease Clinical Trial using placebo; gantenerumab

Hoffmann-La Roche - Recruiting 50 years to 85 years.
- Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Two Year Study to Evaluate the Effect of Subcutaneous RO4909832 on Cognition and Function in Prodromal Alzheimer's Disease With Option for an Additional Two Years of Treatment.
placebo; gantenerumab

Lymphocytic Leukemia, Chronic Clinical Trial using rituximab [MabThera]; fludarabine; cyclophosphamide; chlorambucil

Hoffmann-La Roche - Recruiting 60 years or older.
- Prospective Randomized Study to Compare Efficacy and Safety of RFC-lite (Rituximab, Fludarabine, Cyclophosphamide) Regimen With LR (Rituximab, Chlorambucil) as a First-line Therapy in Patients With B-cell Chronic Lymphocytic Leukemia and Unfavorable Somatic Status.
rituximab [MabThera]; fludarabine; cyclophosphamide; chlorambucil

Hepatitis C, Chronic Clinical Trial

Hoffmann-La Roche - Recruiting 18 years or older.
- Non-Interventional Cohort Study on the Utilization and Impact of Dual and Triple Therapies Based on Pegylated Interferon for the Treatment of Chronic Hepatitis C.

Gastric Cancer Clinical Trial using trastuzumab [Herceptin]; capecitabine; cisplatin

Hoffmann-La Roche - Recruiting 18 years or older.
- .
trastuzumab [Herceptin]; capecitabine; cisplatin

Lymphoma, B-Cell Clinical Trial using rituximab [MabThera/Rituxan]; CHOP

Hoffmann-La Roche - Recruiting 18 years to 80 years.
- A Comparative, Randomized, Parallel-group, Multi-centre, Phase IIIB Study to Investigate the Efficacy of Subcutaneous (SC) Rituximab Versus (IV) Rituximab Both in Combination With CHOP (R-CHOP) in Previously Untreated Patients With CD20 Positive Diffuse Large B-cell Lymphoma (DLBCL).
rituximab [MabThera/Rituxan]; CHOP

Rheumatoid Arthritis Clinical Trial using tocilizumab [RoActemra/Actemra]

Hoffmann-La Roche - Recruiting 18 years or older.
- A Multicenter, Open-Label, Single Arm, Long Term Extension Study of WA 19926 to Describe Safety During Treatment With Tocilizumab in Patients With Early, Moderate to Severe Rheumatoid Arthritis.
tocilizumab [RoActemra/Actemra]

Hepatitis C, Chronic Clinical Trial

Hoffmann-La Roche - Recruiting 18 years or older.
- Prospective Multicenter Observational Trial to Evaluate Correlation Between Liver Biopsy and Transient Elastography in Liver Fibrosis Assessment and Correlation Between Viral Kinetics and Transient Elastography Evolution During Hepatitis C Treatment in a Population of Chronic HCV Infected Patients.

Neoplasms Clinical Trial using RO5520985

Hoffmann-La Roche - Recruiting 18 years or older.
- An Open-label, Multi-center, Dose Escalation Phase I Study of Single Agent RO5520985, Administered as an Intravenous Infusion in Patients With Locally Advanced or Metastatic Solid Tumors..
RO5520985

Gastric Cancer Clinical Trial using pertuzumab [Perjeta]; placebo; trastuzumab [Herceptin]; cisplatin; capecitabine; 5-fluorouracil

Hoffmann-La Roche - Recruiting 18 years or older.
- A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED, MULTICENTER PHASE III STUDY EVALUATING THE EFFICACY AND SAFETY OF PERTUZUMAB IN COMBINATION WITH TRASTUZUMAB AND CHEMOTHERAPY IN PATIENTS WITH HER2-POSITIVE METASTATIC GASTROESOPHAGEAL JUNCTION OR GASTRIC CANCER.
pertuzumab [Perjeta]; placebo; trastuzumab [Herceptin]; cisplatin; capecitabine; 5-fluorouracil

Hepatitis C, Chronic Clinical Trial

Hoffmann-La Roche - Recruiting 18 years or older.
- Non-interventional, Observational Study on Retreatment of Chronic Hepatitis C Patients Previous Treatment Failure, Using Peginterferon Alfa-2a and Ribavirin Based Regimens.

Malignant Melanoma, Neoplasms Clinical Trial using vemurafenib; phenprocoumon

Hoffmann-La Roche - Recruiting 18 years to 70 years.
- A PHASE I, OPEN-LABEL, MULTICENTER, RANDOMINZED, PARALELL STUDY TO INVESTIGATE THE EFFECT OF VEMURAFENIB ON THE PHARMACOKINETICS OF A SINGLE ORAL DOSE OF PHENPROCOUMON IN PATIENTS WITH BRAFV600 MUTATION-POSITIVE METASTATIC MALIGNANCY.
vemurafenib; phenprocoumon

Non-Small Cell Lung Cancer Clinical Trial using erlotinib; placebo; onartuzumab

Hoffmann-La Roche - Recruiting 18 years or older.
- A RANDOMIZED, PHASE III, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ONARTUZUMAB IN COMBINATION WITH ERLOTINIB AS FIRST-LINE TREATMENT FOR PATIENTS WITH MET-POSITIVE UNRESECTABLE STAGE IIIB OR IV NON-SMALL CELL LUNG CANCER (NSCLC) CARRYING AN ACTIVATING EGFR MUTATION.
erlotinib; placebo; onartuzumab

Breast Cancer Clinical Trial using trastuzumab [Herceptin]

Hoffmann-La Roche - Recruiting 18 years or older.
- A Single Arm Multi-center Study Investigating the at Home Administration of Trastuzumab Subcutaneous Vial for the Treatment of Patients With HER2-positive Early Breast Cancer..
trastuzumab [Herceptin]

Breast Cancer Clinical Trial

Hoffmann-La Roche - Recruiting 18 years or older.
- CLINICAL PRACTICE SURVEILLANCE OF THE USE OF HERCEPTIN SUBCUTANEOUS IN PATIENTS WITH HER2-POSITIVE EARLY BREAST CANCER (HerSCin).

Neoplasms Clinical Trial using Cobimetinib; MPDL3280A

Hoffmann-La Roche - Recruiting 18 years or older.
- A Phase 1b Study of the Safety and Pharmacology of MPDL3280A Administered With Cobimetinib in Patients With Locally Advanced or Metastatic Solid Tumors.
Cobimetinib; MPDL3280A

Colorectal Cancer Clinical Trial

Hoffmann-La Roche - Recruiting 18 years or older.
- Observational Study of Avastin Plus 5-FU Based Chemotherapy as First Line Treatment for Chinese Patients With Metastatic Colorectal Cancer..

Cardiovascular Disease, Rheumatoid Arthritis Clinical Trial using tocilizumab [RoActemra/Actemra]; etanercept

Hoffmann-La Roche - Recruiting 50 years or older.
- A Clinical Outcomes Study to Evaluate the Effects of IL-6 Receptor Blockade With Tocilizumab (TCZ) in Comparison With Etanercept (ETA) on the Rate of Ischemic Cardiovascular Events in Patients With Moderate to Severe Rheumatoid Arthritis (RA).
tocilizumab [RoActemra/Actemra]; etanercept

Colorectal Cancer Clinical Trial using bevacizumab [Avastin]; mFOLFOX6

Hoffmann-La Roche - Recruiting 18 years or older.
- A Multi-center, Open-label Clinical Trial to Evaluate the Objective Response Rate of Bevacizumab in Combination With Modified FOLFOX-6 Followed by One Year of Maintenance With Bevacizumab Alone in Patients With Initially Not or Borderline Resectable Colorectal Liver Metastases (The CLMO-001 Trial).
bevacizumab [Avastin]; mFOLFOX6

Depression Disorder, Major Clinical Trial using RO4995819; Placebo

Hoffmann-La Roche - Recruiting 18 years to 65 years.
- A Multi Center, Randomized, Double-blind, Placebo Controlled, Parallel-group Study to Investigate the Efficacy and Safety of RO4995819 Versus Placebo, as Adjunctive Therapy in Patients With Major Depressive Disorder Having Inadequate Response to Ongoing Antidepressant Treatment (ARTDeCo).
RO4995819; Placebo

Neoplasms Clinical Trial using zirconium-89-labeled RO5479599; RO5479599; cetuximab; erlotinib

Hoffmann-La Roche - Recruiting 18 years or older.
- Phase Ia/Ib, Open-label, Multicenter, Dose-escalation Study Followed by an Extension Phase to Evaluate Safety, Pharmacokinetics and Activity of RO5479599, a Glycoengineered Antibody Against HER3, Administered Either Alone (Part A) or in Combination With Cetuximab (Part B) or in Combination With Erlotininb (Part C) in Patients With Metastatic and/or Locally Advanced Malignant HER3-positive Solid Tumors of Ephitelian Cell Origin.
zirconium-89-labeled RO5479599; RO5479599; cetuximab; erlotinib

Breast Cancer Clinical Trial using pertuzumab; trastuzumab; Aromatase Inhibitor; Induction Chemotherapy

Hoffmann-La Roche - Recruiting 18 years or older.
- A Randomized, Two-arm, Open-label, Multicenter Phase II Trial Assessing the Efficacy and Safety of Pertuzumab Given in Combination With Trastuzumab Plus an Aromatase Inhibitor in First Line Patients With HER2-positive and Hormone Receptor-positive Advanced (Metastatic or Locally Advanced) Breast Cancer..
pertuzumab; trastuzumab; Aromatase Inhibitor; Induction Chemotherapy

Anemia, Kidney Disease, Chronic Clinical Trial using methoxy polyethylene glycol-epoetin beta [Mircera]

Hoffmann-La Roche - Recruiting 18 years or older.
- Comparative Study to Assess the Effect of the Altitude on Dose Requirements of Methoxy Polyethylene Glycol-epoetin Beta to Correct Haemoglobin Levels in Chronic Renal Anemia in Pre-dialysis and Dialysis Patients.
methoxy polyethylene glycol-epoetin beta [Mircera]

Rheumatoid Arthritis Clinical Trial

Hoffmann-La Roche - Recruiting 18 years or older.
- An Observational Study on the Efficacy and Safety of MabThera (Rituximab) in seroPOSITIVE TNF IR Patients With Severe Active Rheumatoid Arthritis in Routine Clinical Practice (POSITIVE TRIAL).

Hepatitis C, Chronic Clinical Trial

Hoffmann-La Roche - Recruiting 18 years or older.
- Prospective Observational Study on Predictors of On-treatment Response and Sustained Virological Response in a Cohort of HCV-infected Patients Treated With Pegylated Interferons in Georgia.

Kidney Transplantation Clinical Trial

Hoffmann-La Roche - Recruiting 18 years or older.
- Prospective, Open-label, Non-interventional Study for the Follow-up of Renal Function in de Novo Kidney Transplant Patients Treated With Immunosuppressive Therapy Containing CellCept in Routine Clinical Practice (ORANGE Study).

Colorectal Cancer Clinical Trial

Hoffmann-La Roche - Recruiting 18 years or older.
- AN OPEN-LABEL, MULTICENTER, NON-INTERVENTION, OBSERVATIONAL STUDY TO ASSESS THE EFFECT OF FIRST LINE BEVACIZUMAB TREATMENT WITH FLUOROPYRIMIDINE-BASED CHEMOTHERAPY (CTX) IN PATIENTS WITH METASTATIC COLORECTAL CANCER.

Wegener's Granulomatosis, Microscopic Polyangiitis Clinical Trial using rituximab [MabThera/Rituxan]

Hoffmann-La Roche - Recruiting 2 years to 17 years.
- A PHASE IIa, INTERNATIONAL, MULTICENTER, OPEN-LABEL, UNCONTROLLED STUDY TO EVALUATE THE SAFETY AND PHARMACOKINETICS OF 4 x 375 mg/m2 INTRAVENOUS RITUXIMAB IN PEDIATRIC PATIENTS WITH SEVERE GRANULOMATOSIS WITH POLYANGIITIS (WEGENER S) OR MICROSCOPIC POLYANGIITIS.
rituximab [MabThera/Rituxan]

Colorectal Cancer Clinical Trial

Hoffmann-La Roche - Recruiting 18 years or older.
- Non-interventional Local Study to Describe the Safety, Tolerability and Efficacy of Bevacizumab in Combination With Standard Chemotherapy Regimens as First Line in Patients With Metastatic Cancer of the Colon or the Rectum.

Hepatitis B, Chronic Clinical Trial

Hoffmann-La Roche - Recruiting 18 years or older.
- A Phase 4, Blood Sample Collection Study For Exploratory Evaluation of the Association of Single Nucleotide Polymorphisms With Treatment Responses From Subjects With HBE-Antigen Positive or Negative Chronic Hepatitis B, Who Received Therapy for Hepatitis B With Peginterferon Alfa-2A 40KD (PEG-IFN) +/- Nucleos(t)Ide Analogue.

Rheumatoid Arthritis Clinical Trial

Hoffmann-La Roche - Recruiting 20 years or older.
- .

Asthma Clinical Trial

Hoffmann-La Roche - Recruiting 12 years or older.
- A Prospective Observational Study To Evaluate Predictors of Clinical Response To Omalizumab.

Breast Cancer Clinical Trial using trastuzumab [Herceptin]; taxane; anthracycline

Hoffmann-La Roche - Recruiting 18 years or older.
- NATIONAL PHASE IIIB PROSPECTIVE, TWO-COHORT NON-RANDOMIZED, MULTI-CENTRE, OPEN LABEL STUDY TO ASSESS THE SAFETY OF SUBCUTANEOUS TRASTUZUMAB AND MOLECULAR BIOMARKERS IN PATIENTS WITH EARLY AND LOCALLY ADVANCED HER2-POSITIVE BREAST CANCER.
trastuzumab [Herceptin]; taxane; anthracycline

Non-Small Cell Lung Cancer Clinical Trial using MPDL3280A; docetaxel

Hoffmann-La Roche - Recruiting 18 years or older.
- A PHASE III, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF MPDL3280A (ANTI-PD-L1 ANTIBODY) COMPARED WITH DOCETAXEL IN PATIENTS WITH NON-SMALL CELL LUNG CANCER AFTER FAILURE WITH PLATINUM-CONTAINING CHEMOTHERAPY.
MPDL3280A; docetaxel

Breast Cancer Clinical Trial using Taxane chemotherapy; Perjeta (pertuzumab); Herceptin (trastuzumab)

Hoffmann-La Roche - Recruiting 18 years or older.
- An Open-label, Multicentre, Phase IIIb Study With Intravenous Administration of Pertuzumab, Subcutaneous Trastuzumab, and a Taxane in Patients With HER2-positive Metastatic Breast Cancer.
Taxane chemotherapy; Perjeta (pertuzumab); Herceptin (trastuzumab)

Non-Hodgkin's Lymphoma Clinical Trial using RO5072759; rituximab [MabThera/Rituxan]; chemotherapy

Hoffmann-La Roche - Recruiting 18 years or older.
- A Multicentre, Phase III, Open Label, Randomized Study in Previously Untreated Patients With Advanced Indolent Non-Hodgkin's Lymphoma Evaluating the Benefit of GA101 (RO5072759) + Chemotherapy Compared to Rituximab + Chemotherapy Followed by GA101 or Rituximab Maintenance Therapy in Responders..
RO5072759; rituximab [MabThera/Rituxan]; chemotherapy

Neoplasms Clinical Trial using RO5509554; paclitaxel

Hoffmann-La Roche - Recruiting 18 years or older.
- Open-label, Multicenter, Dose Escalation Phase Ia/Ib Study With Expansion Phase to Evaluate Safety, Pharmacokinetics and Activity of RO5509554, Administered as an Intravenous Infusion as Monotherapy and in Combination With Paclitaxel in Patients With Advanced Solid Tumors..
RO5509554; paclitaxel

Breast Cancer Clinical Trial using taxane; pertuzumab; trastuzumab [Herceptin]

Hoffmann-La Roche - Recruiting 18 years or older.
- A Multicenter, Open-label, Single-arm Study of a Pertuzumab in Combination With Trastuzumab and a Taxane in First Line Treatment of Patients With HER2- Positive Advanced (Metastatic or Locally Recurrent) Breast Cancer.
taxane; pertuzumab; trastuzumab [Herceptin]

Ovarian Cancer Clinical Trial using pertuzumab; placebo; chemotherapy

Hoffmann-La Roche - Recruiting 18 years or older.
- A TWO-PART, RANDOMIZED PHASE III, DOUBLE-BLIND, MULTICENTER TRIAL ASSESSING THE EFFICACY AND SAFETY OF PERTUZUMAB IN COMBINATION WITH STANDARD CHEMOTHERAPY VS. PLACEBO PLUS STANDARD CHEMOTHERAPY IN WOMEN WITH RECURRENT PLATINUM-RESISTANT EPITHELIAL OVARIAN CANCER AND LOW HER3 mRNA EXPRESSION.
pertuzumab; placebo; chemotherapy

Peritoneal Neoplasms Clinical Trial

Hoffmann-La Roche - Recruiting 18 years or older.
- Non-interventional Surveillance Study (NIS) on First-line (FL) Bevacizumab (Avastin) in Combination With Carboplatin/Paclitaxel in Patients With Advanced Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

Breast Cancer, Gastric Cancer Clinical Trial using trastuzumab emtansine; capecitabine

Hoffmann-La Roche - Recruiting 18 years or older.
- PHASE I FOLLOWED BY PHASE II STUDY OF THE COMBINATION OF TRASTUZUMAB EMTANSINE (T-DM1) AND CAPECITABINE IN HER2-POSITIVE METASTATIC BREAST CANCER AND HER2-POSITIVE LOCALLY ADVANCED OR METASTATIC GASTRIC CANCER PATIENTS.
trastuzumab emtansine; capecitabine

Non-Small Cell Lung Cancer Clinical Trial

Hoffmann-La Roche - Recruiting 18 years or older.
- Observational, Post-authorization, Prospective Study for Evaluating Patterns of Disease Progression in Patients With Advanced Non-small-cell Lung Carcinoma (NSCLC) Harbouring EGFR Activating Mutations Treated With Erlotinib in First Line..

Hepatitis B, Chronic Clinical Trial

Hoffmann-La Roche - Recruiting 18 years or older.
- A MULTICENTER, PROSPECTIVE, OBSERVATIONAL, NON-INTERVENTIONAL COHORT STUDY IN CHINESE SUBJECTS WITH HBeAg NEGATIVE CHRONIC HEPATITIS B (CHB) RECEIVING THERAPY WITH PEGINTERFERON ALFA.

Ovarian Cancer Clinical Trial using bevacizumab [Avastin]; Carboplatin; paclitaxel

Hoffmann-La Roche - Recruiting 18 years or older.
- A Randomized, Open-label, Phase II Study Assessing the Efficacy and the Safety of Bevacizumab in Neoadjuvant Therapy in Patients With FIGO Stage IIIC/IV Ovarian, Tubal or Peritoneal Adenocarcinoma, Initially Unresectable..
bevacizumab [Avastin]; Carboplatin; paclitaxel

Myelogenous Leukemia, Acute Clinical Trial using RO5503781; cytarabine; Anthracycline

Hoffmann-La Roche - Recruiting 18 years or older.
- A MULTI-CENTER, OPEN-LABEL, PHASE 1/1B STUDY OF ESCALATING DOSES OF RO5503781 ADMINISTERED ORALLY AS 1) A SINGLE AGENT, 2) IN COMBINATION WITH CYTARABINE, OR 3) WITH CYTARABINE AND ANTHRACYCLINE IN PATIENTS WITH ACUTE MYELOGENOUS LEUKEMIA (AML).
RO5503781; cytarabine; Anthracycline

Non-Small Cell Lung Cancer Clinical Trial

Hoffmann-La Roche - Recruiting 65 years or older.
- Therapeutic Strategies Including Avastin as 1st Line Therapy in Elderly Patients Suffering From Advanced (IIIB/IV Stage) Non-squamous Non-small Cell Lung Cancer, in Routine Clinical Practice..

Liver Cancer Clinical Trial using onartuzumab; sorafenib

Hoffmann-La Roche - Recruiting 18 years or older.
- A PHASE Ib, OPEN-LABEL STUDY EVALUATING THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF ONARTUZUMAB GIVEN AS A SINGLE AGENT AND IN COMBINATION WITH SORAFENIB IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA (HCC).
onartuzumab; sorafenib

Basal Cell Carcinoma Clinical Trial using vismodegib; Placebo

Hoffmann-La Roche - Recruiting 18 years or older.
- A Randomized, Double-Blind, Placebo-Controlled, Phase II Study To Assess The Efficacy And Safety Of Oral Vismodegib For The Treatment Of Basal Cell Carcinoma Preceding Excision By Mohs Micrographic Surgery.
vismodegib; Placebo

Anemia Clinical Trial

Hoffmann-La Roche - Recruiting 18 years or older.
- An Observational, Prospective Study to Evaluate the Hemoglobin Levels in Non-dialysis Chronic Kidney Disease Subjects With Renal Anaemia, Treated With MIRCERAr (Methoxy-polyethylene-glycol-epoetin Beta) (OPTIMA)..

Neoplasms Clinical Trial using Vemurafenib; Cobimetinib; Onartuzumab

Hoffmann-La Roche - Recruiting 18 years or older.
- A PHASE Ib, OPEN-LABEL STUDY EVALUATING THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF ONARTUZUMAB IN COMBINATION WITH VEMURAFENIB AND/OR COBIMETINIB IN PATIENTS WITH ADVANCED SOLID MALIGNANCIES.
Vemurafenib; Cobimetinib; Onartuzumab

Non-Small Cell Lung Cancer Clinical Trial using MPDL3280A

Hoffmann-La Roche - Recruiting 18 years or older.
- A PHASE II, MULTICENTER, SINGLE-ARM STUDY OF MPDL3280A IN PATIENTS WITH PD-L1-POSITIVE LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER.
MPDL3280A

Schizophrenia Clinical Trial using bitopertin [RO4917838]; Placebo

Hoffmann-La Roche - Recruiting 18 years or older.
- Phase III, Multi-center, Randomized, 12-week, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of RO4917838 in Patients With Sub-optimally Controlled Symptoms of Schizophrenia Treated With Antipsychotics Followed by a 40-week Double-blind, Parallel-group, Placebo-controlled Treatment Period..
bitopertin [RO4917838]; Placebo

Rheumatoid Arthritis Clinical Trial using tocilizumab [RoActemra/Actemra]

Hoffmann-La Roche - Recruiting 18 years or older.
- Local Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of Tocilizumab in Patients With Active Rheumatoid Arthritis on Background Non-biologic DMARDs Who Have an Inadequate Response to Current Non-biologic DMARD.
tocilizumab [RoActemra/Actemra]

Juvenile Idiopathic Arthritis Clinical Trial using RoActemra/Actemra (tocilizumab)

Hoffmann-La Roche - Recruiting 2 years or older.
- Long-term, Interventional, Open Label Extension Study Evaluating the Safety of Tocilizumab Treatment in Patients With Polyarticular-course Juvenile Idiopathic Arthritis From Poland and Russia Who Completed the Global, Multinational Trial (WA19977)..
RoActemra/Actemra (tocilizumab)

Hepatitis C, Chronic Clinical Trial

Hoffmann-La Roche - Recruiting 18 years or older.
- Open-label, Multicenter, Non-comparative, Prospective Observational Study to Evaluate Efficacy and Safety of Combined Ribavirin and Peginterferon Alfa-2a (40 kDa) Therapy in Patients With Chronic Hepatitis C (CHC) and Compensated Liver Cirrhosis in Real Clinical Practice.

Gastric Cancer Clinical Trial using trastuzumab emtansine; taxane

Hoffmann-La Roche - Recruiting 18 years or older.
- A Randomized, Multicenter, Adaptive Phase II/III Study To Evaluate The Efficacy And Safety Of Trastuzumab Emtansine (T-DM1) Versus Taxane (Docetaxel Or Paclitaxel) In Patients With Previously Treated Locally Advanced Or Metastatic Her2-Positive Gastric Cancer, Including Adenocarcinoma Of The Gastroesophageal Junction.
trastuzumab emtansine; taxane

Gastric Cancer Clinical Trial using Onartuzumab; Placebo; mFOLFOX6

Hoffmann-La Roche - Recruiting 18 years or older.
- A Randomized, Phase III, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating The Efficacy And Safety Of Onartuzumab (MetMAb) In Combination With 5-Fluorouracil, Folinic Acid, And Oxaliplatin (mFOLFOX6) In Patients With Metastatic Her2-Negative, Met-Positive Gastroesophageal Cancer (MetGastric).
Onartuzumab; Placebo; mFOLFOX6

Malignant Melanoma Clinical Trial using vemurafenib; Placebo

Hoffmann-La Roche - Recruiting 18 years or older.
- A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Vemurafenib (RO5185426) Adjuvant Therapy in Patients With Surgically Resected, Cutaneous BRAF Mutant Melanoma at High Risk for Recurrence.
vemurafenib; Placebo

Rheumatoid Arthritis Clinical Trial

Hoffmann-La Roche - Recruiting 18 years or older.
- A Multi-Center, Non-inteRventional Study in rheumatOid Arthritis patientS Treated With Tocilizumab in Serbia- ACROSS; (Part of Global Umbrella Project).

Influenza Clinical Trial using oseltamivir [Tamiflu]

Hoffmann-La Roche - Recruiting N/A to 12 years.
- AN OPEN-LABEL, RANDOMIZED, ADAPTIVE, TWO-ARM, MULTICENTER TRIAL TO EVALUATE PHARMACOKINETICS AND PHARMACODYNAMICS OF TWO DOSES OF OSELTAMIVIR (TAMIFLUr) IN THE TREATMENT OF INFLUENZA IN IMMUNOCOMPROMISED CHILDREN, FROM 2 WEEKS TO LESS THAN 13 YEARS OF AGE, WITH CONFIRMED INFLUENZA INFECTION.
oseltamivir [Tamiflu]

Malignant Melanoma, Neoplasms Clinical Trial using vemurafenib; digoxin

Hoffmann-La Roche - Recruiting 18 years or older.
- A Phase I, Open-Label, Multicenter, 3-Period, Fixed-Sequence Study To Investigate The Effect Of Vemurafenib On The Pharmacokinetics Of A Single Dose Of Digoxin In Patients With BRAFV600 Mutation-Positive Metastatic Malignancy.
vemurafenib; digoxin

Idiopathic Pulmonary Fibrosis Clinical Trial using lebrikizumab; placebo

Hoffmann-La Roche - Recruiting 40 years or older.
- A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, STUDY TO ASSESS THE EFFICACY AND SAFETY OF LEBRIKIZUMAB IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS.
lebrikizumab; placebo

Lymphoma Clinical Trial using MabThera/Rituxan; Standard chemotherapy

Hoffmann-La Roche - Recruiting 18 years to 80 years.
- A Single Arm, Multicentre, Phase IIIb Study to Evaluate Safety, Efficacy and Pharmacokinetic (PK) of Subcutaneous (SC) Rituximab Administered During Induction Phase or Maintenance in Previously Untreated Patients With CD20+ Diffuse Large B Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL).
MabThera/Rituxan; Standard chemotherapy

Healthy Volunteer Clinical Trial using RO4995819

Hoffmann-La Roche - Recruiting 18 years to 65 years.
- A Randomized, Single Dose, Open-label, Two Parts, Two and Three Period Cross-over Study to Investigate the Relative Bioavailability of Two Tablet Formulations and the Effect of Fasting Following Oral Administration of RO4995819 in Healthy Subjects.
RO4995819

Rheumatoid Arthritis Clinical Trial

Hoffmann-La Roche - Recruiting 18 years or older.
- Multinational, Multicenter, Non Interventional Study, in Patients With Rheumatoid Arthritis (RA) Treated With Tocilizumab..

Schizophrenia Clinical Trial

Hoffmann-La Roche - Recruiting 18 years or older.
- .

Healthy Volunteer Clinical Trial using Posaconozole; RO5424802

Hoffmann-La Roche - Recruiting 18 years to 55 years.
- An Open-Label, Three-Period, Fixed Sequence Study to Investigate the Effect of Multiple Oral Doses of Posaconazole, a Potent Cytochrome P450 3A Inhibitor, on the Single Dose Pharmacokinetics of RO5424802 in Healthy Subjects.
Posaconozole; RO5424802

Schizophrenia Clinical Trial using RO5545965; Placebo; risperidone

Hoffmann-La Roche - Recruiting 18 years to 60 years.
- A SINGLE-CENTER, RANDOMIZED, INVESTIGATOR/SUBJECT-BLIND, MULTIPLE-DOSE, PLACEBO-CONTROLLED, PARALLEL STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY AND PHARMACOKINETICS OF RO5545965 IN PATIENTS WITH SCHIZOPHRENIA ON RISPERIDONE..
RO5545965; Placebo; risperidone

Myelogenous Leukemia, Acute Clinical Trial using RO5429083; cytarabine

Hoffmann-La Roche - Recruiting 18 years or older.
- Open Label, Multicenter, Dose Escalation Phase 1a/b Study of RO5429083, Administered as Intravenous Infusion Alone or in Combination With Cytarabine in Patients With Acute Myelogenous Leukemia (AML)..
RO5429083; cytarabine

Rheumatoid Arthritis Clinical Trial using tocilizumab [RoActemra/Actemra]; methotrexate

Hoffmann-La Roche - Recruiting 18 years or older.
- Randomised, Phase IV, Placebo-controlled, Comparative Study to Evaluate the Efficacy and Safety of Tapering Methotrexate (MTX) Dosage Versus Maintaining the Dosage in Patients With Severe Active Rheumatoid Arthritis (RA) Who Have Demonstrated an Inadequate Response to Prior Conventional Disease-modifying Anti-rheumatic Drugs (DMARDs) Treatment and Have Initiated RoActemrar (Tocilizumab, TCZ) in Combination With MTX.
tocilizumab [RoActemra/Actemra]; methotrexate

Anemia Clinical Trial

Hoffmann-La Roche - Recruiting 18 years or older.
- Non-interventional Study on the Use of Mircera in the Treatment of Chronic Renal Anemia in Patients With Chronic Kidney Disease Stages III-IV Not on Dialysis and in Patients on Stage V on Hemodialysis.

Rheumatoid Arthritis Clinical Trial

Hoffmann-La Roche - Recruiting 18 years or older.
- Multicenter, Post-marketing, Non-interventional, Observational Study in RA Patients Treated With Tocilizumab..

Rheumatoid Arthritis Clinical Trial

Hoffmann-La Roche - Recruiting 18 years or older.
- Mon-ACT: A Multi-center, Non-interventional Study in Rheumatoid Arthritis (RA) Patients Treated With Tocilizumab in Monotherapy.

Pancreatic Cancer Clinical Trial

Hoffmann-La Roche - Recruiting 18 years or older.
- Impact on Survival of Cutaneous Reactions in Erlotinib Plus Gemcitabine Treated Patients With Metastatic Pancreatic Cancer Under Conditions of Daily Routine Practice.

Gastric Cancer Clinical Trial

Hoffmann-La Roche - Recruiting 18 years or older.
- A NON-INTERVENTIONAL, REGISTRY STUDY FOR CHINESE GASTRIC CANCER PATIENTS WITH HER2 STATUS: CLINICAL AND PATHOLOGICAL CHARACTERISTICS, TREATMENT PATTERNS AND CLINICAL OUTCOMES.

Rheumatoid Arthritis Clinical Trial using tocilizumab [RoActemra/Actemra]; DMARDs

Hoffmann-La Roche - Recruiting 18 years or older.
- A NATIONAL, OPEN-LABEL, SINGLE-ARM, PHASE IIIB STUDY TO EVALUATE THE EFFICACY OF WEEKLY TOCILIZUMAB SUBCUTANEOUS, ADMINISTERED AS MONOTHERAPY OR IN COMBINATION WITH METHOTREXATE AND/OR OTHER DMARDS IN RHEUMATOID ARTHRITIS (RA) PATIENTS..
tocilizumab [RoActemra/Actemra]; DMARDs

Healthy Volunteer Clinical Trial using tocilizumab [RoActemra/Actemra]; placebo

Hoffmann-La Roche - Recruiting 18 years to 65 years.
- A Single Blind Phase IV Pharmacodynamic Study to Evaluate Neutrophil Distribution Kinetics and Function Following Single-Dose Tocilizumab Treatment in Healthy Subjects.
tocilizumab [RoActemra/Actemra]; placebo

Rheumatoid Arthritis Clinical Trial

Hoffmann-La Roche - Recruiting 18 years or older.
- A Prospective, Non-interventional Multi-center Observational Study to Evaluate the Long-term Effectiveness and Safety of Tocilizumab in Patients With Active Rheumatoid Arthritis in Daily Practice.

Lymphocytic Leukemia, Chronic Clinical Trial

Hoffmann-La Roche - Recruiting 18 years or older.
- Non Interventional Study Aimed to Describe the Management of Relapse or Refractory Chronic Lymphocytic Leukemia (CLL) Patients Retreated by MabThera.

Colorectal Cancer Clinical Trial

Hoffmann-La Roche - Recruiting 75 years or older.
- Non Interventional Study Evaluating Efficacy and Safety in a Cohort of Elderly Patients of First Line Therapy With Avastin r Regimen for Metastatic Colorectal Cancer..

Rheumatoid Arthritis Clinical Trial

Hoffmann-La Roche - Recruiting 20 years or older.
- A Non-interventional Study for Relative Efficacy Outcome of Rituximab Treatment in RA Patients Who Have Inadequate Response or Have Been Intolerant to a First Anti-TNF Agent.

Schizophrenia Clinical Trial

Hoffmann-La Roche - Recruiting 18 years or older.
- A Non-Interventional Prospective Cohort Study of Patients With Persistent Symptoms of Schizophrenia to Describe The Course and Burden of Illness.

Rheumatoid Arthritis Clinical Trial

Hoffmann-La Roche - Recruiting 18 years or older.
- Non-interventional, Prospective, Multicenter Study to Assess Efficacy and Safety of MabtheRA (Rituximab) in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response or Intolerance to One Anti-TNF Agent - FAST 2 SWITCH Program.

Non-Small Cell Lung Cancer Clinical Trial using erlotinib [Tarceva]

Hoffmann-La Roche - Recruiting 18 years or older.
- Phase IIIb, Open-label Study of Erlotinib (Tarcevar) Treatment in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Who Present Activating Mutations in the Tyrosine Kinase Domain of the Epidermal Growth Factor Receptor (ESSENCE).
erlotinib [Tarceva]

Rheumatoid Arthritis Clinical Trial

Hoffmann-La Roche - Recruiting 18 years or older.
- HAQIMONO a Non-interventional National Multicenter Study, Observing RA Patients Treated With Tocilizumab in Mono-therapy, i.e. Without Combination With DMARD.

Colorectal Cancer Clinical Trial

Hoffmann-La Roche - Recruiting 70 years or older.
- Prospective Non-interventional Study to Collect Data on the Use of Avastin and Conventional Chemotherapy for the Treatment of Previously Untreated Metastatic Colorectal Cancer in Patients >/= 70 Years.

Colorectal Cancer, Neoplasm Metastasis Clinical Trial using bevacizumab [Avastin]; 5-FU based doublet chemotherapy

Hoffmann-La Roche - Recruiting 18 years to 75 years.
- A Multi-center, Single-arm, Pilot Study of 5-FU Based Doublet Chemotherapy Plus Bevacizumab as Neoadjuvant Therapy for Patients With Previously Untreated Unresectable Liver-only Metastases From Colorectal Cancer.
bevacizumab [Avastin]; 5-FU based doublet chemotherapy

Juvenile Idiopathic Arthritis Clinical Trial using tocilizumab [RoActemra/Actemra]

Hoffmann-La Roche - Recruiting 2 years to 17 years.
- A Phase IV Study to Evaluate Decreased Dose Frequency in Patients With Systemic Juvenile Arthritis (SJIA) Who Experience Laboratory Abnormalities During Treatment With Tocilizumab.
tocilizumab [RoActemra/Actemra]

Kidney Disease, Chronic Clinical Trial

Hoffmann-La Roche - Recruiting 18 years or older.
- A Non Interventional Study to Assess the Hemoglobin Level Depending on the Comorbidity Index in Chronic Kidney Disease (CDK) Patients Not in Dialysis Treated With Mircera.

Colorectal Cancer Clinical Trial using bevacizumab [Avastin]; leucovorin; 5-fluorouracil; irinotecan; oxaliplatin; capecitabine [Xeloda]; fluoropyrimidine-based chemotherapy

Hoffmann-La Roche - Recruiting 18 years to 75 years.
- STEAM (SEQUENTIAL TRIPLET AND AVASTIN MAINTENANCE): FOLFOXIRI/BEVACIZUMAB REGIMENS (CONCURRENT AND SEQUENTIAL) VS. FOLFOX/BEVACIZUMAB IN FIRST-LINE METASTATIC COLORECTAL CANCER.
bevacizumab [Avastin]; leucovorin; 5-fluorouracil; irinotecan; oxaliplatin; capecitabine [Xeloda]; fluoropyrimidine-based chemotherapy

Breast Cancer Clinical Trial using trastuzumab emtansine; trastuzumab

Hoffmann-La Roche - Recruiting 18 years or older.
- A Randomized, Multicenter, Open-Label Phase III Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy for Patients With HER2-Positive Primary Breast Cancer Who Have Residual Tumor Present Pathologically in the Breast or Axillary Lymph Nodes Following Preoperative Therapy.
trastuzumab emtansine; trastuzumab

Non-Small Cell Lung Cancer Clinical Trial

Hoffmann-La Roche - Recruiting 18 years or older.
- AVAdeno: Non-interventional Study of Avastin 1st Line Therapy in Adenocarcinoma Patients of the Lung.

Neoplasms Clinical Trial using RO5503781; posaconazole

Hoffmann-La Roche - Recruiting 18 years or older.
- A MULTIPLE-CENTER, OPEN-LABEL CLINICAL PHARMACOLOGY STUDY WITH RO5503781, AN MDM2 ANTAGONIST, IN PATIENTS WITH SOLID TUMORS TO DETERMINE: PART 1 ONE-SEQUENCE, 2-PERIOD CROSSOVER DESIGN TO INVESTIGATE THE EFFECT OF POSACONAZOLE, A STRONG CYP3A4 INHIBITOR, ON THE PHARMACOKINETICS AND PHARMACODYNAMICS OF RO5503781 PART 2 A RANDOMIZED, SINGLE DOSE, 3 PERIOD CROSSOVER DESIGN TO INVESTIGATE THE RELATIVE BIOAVAILABILITY OF TWO NEW RO5503781 TABLET FORMULATIONS FOLLOWING ORAL ADMINISTRATION.
RO5503781; posaconazole

Neoplasms Clinical Trial using RO5429083

Hoffmann-La Roche - Recruiting 18 years or older.
- Open-Label Multicenter 2-Arm Phase I Study of RO5429083 With Dose-Escalation and Extension Cohorts, and Imaging Cohorts With RO5429083 and 89Zr-labeled RO5429083, in Patients With Metastatic and/or Locally Advanced, CD44-Expressing, Malignant Solid Tumors.
RO5429083

Breast Cancer Clinical Trial

Hoffmann-La Roche - Recruiting 18 years or older.
- Breast Cancer Care (BRECC) Registry - Development of a Breast Cancer Registry to Determine the Magnitude of Breast Cancer and Current Clinical Care Patterns in Kenya.

Breast Cancer Clinical Trial using trastuzumab emtansine

Hoffmann-La Roche - Recruiting 18 years or older.
- A Phase I, Open Label, Parallel Group, Pharmacokinetic Study of Trastuzumab Emtansine in Patients With HER2-Positive Metastatic Breast Cancer and Normal or Reduced Hepatic Function.
trastuzumab emtansine

Malignant Melanoma Clinical Trial using vemurafenib

Hoffmann-La Roche - Recruiting 12 years to 17 years.
- An Open-label, Multicenter, Single-arm, Phase I Dose-escalation With Efficacy Tail Extension Study of RO5185426 in Pediatric Patients With Surgically Incurable and Unresectable Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations Mutations.
vemurafenib

Rheumatoid Arthritis Clinical Trial

Hoffmann-La Roche - Recruiting 18 years or older.
- A Global Comparative Observational Study In Rheumatoid Arthritis (RA) Patients Who Are Treated With A TNF Inhibitor Or Tocilizumab As The First Biologic Therapy.

Non-Small Cell Lung Cancer Clinical Trial using erlotinib [Tarceva]

Hoffmann-La Roche - Recruiting 18 years or older.
- Open Label Study of Erlotinib (Tarcevar) as Single Agent First Line Treatment of Patients With Locally Advanced or Metastatic Lung Adenocarcinoma With Activating Epidermal Growth Factor Receptor (EGFR) Mutations.
erlotinib [Tarceva]

Gastric Cancer Clinical Trial using trastuzumab [Herceptin]; Oxaliplatin; capecitabine; Radiation

Hoffmann-La Roche - Recruiting 18 years to 75 years.
- Safety and Tolerability of Oxaliplatin-Capecitabine-Trastuzumab Combination and Chemoradiotherapy in Adjuvant Setting in Operated HER2+ Patients With Gastric or Gastroesophageal Junction Adenocarcinoma: A Phase II Study (TOXAG Study).
trastuzumab [Herceptin]; Oxaliplatin; capecitabine; Radiation

Neoplasms Clinical Trial using vemurafenib

Hoffmann-La Roche - Recruiting 18 years or older.
- An Open Label, Phase I Study to Evaluate the Impact of Severe Hepatic Impairment on the Pharmacokinetics and Safety of Vemurafenib in BRAF V600 Mutation Positive Cancer Patients.
vemurafenib

Giant Cell Arteritis Clinical Trial using tocilizumab [RoActemra/Actemra]; tocilizumab placebo; prednisone; prednisone placebo

Hoffmann-La Roche - Recruiting 50 years or older.
- A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF TOCILIZUMAB IN SUBJECTS WITH GIANT CELL ARTERITIS.
tocilizumab [RoActemra/Actemra]; tocilizumab placebo; prednisone; prednisone placebo

Breast Cancer Clinical Trial using trastuzumab [Herceptin]

Hoffmann-La Roche - Recruiting 18 years or older.
- An Open-label, Randomized, Multicenter Phase III Study in Patients With HER2-positive Metastatic Breast Cancer Responding to First Line Treatment With Intravenous Trastuzumab for at Least 3 Years and Investigating Patient Preference for Subcutaneous Trastuzumab.
trastuzumab [Herceptin]

Non-Small Cell Lung Cancer Clinical Trial

Hoffmann-La Roche - Recruiting 18 years or older.
- Efficacy and Safety of erLotinib (Tarcevar ) Therapy in patiEnts With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) , Subtype adEnocarcinoma, Who Have Good performaNce sTatus (PS 0-1) - ELEMENT.

Ovarian Cancer Clinical Trial

Hoffmann-La Roche - Recruiting 18 years or older.
- AN OBSERVATIONAL STUDY OF AVASTINr (BEVACIZUMAB) AS FIRST LINE THERAPY IN PATIENTS WITH ADVANCED OVARIAN CANCER.

Non-Small Cell Lung Cancer Clinical Trial using MPDL3280A; docetaxel

Hoffmann-La Roche - Recruiting 18 years or older.
- A PHASE II, OPEN-LABEL, MULTICENTER, RANDOMIZED, PHASE II STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF MPDL3280A (ANTI-PD-L1 ANTIBODY) COMPARED WITH DOCETAXEL IN PATIENTS WITH NON-SMALL CELL LUNG CANCER AFTER PLATINUM FAILURE.
MPDL3280A; docetaxel

Chronic Lymphocytic Leukemia Clinical Trial using obinutuzumab; chemotherapy

Hoffmann-La Roche - Recruiting 18 years or older.
- A Multicenter, Open-label, Single-arm, Phase IIIb, International Study Evaluating the Safety of Obinutuzumab Alone or in Combination With Chemotherapy in Patients With Previously Untreated or Relapsed/Refractory Chronic Lymphocytic Leukemia.
obinutuzumab; chemotherapy

Down Syndrome Clinical Trial

Hoffmann-La Roche - Recruiting 12 years to 30 years.
- A Screening Protocol to Assess Adult and Adolescent Individuals With Down Syndrome for Eligibility to Participate in an Upcoming Study to Evaluate the Efficacy, Safety and Tolerability of RG1662 (Study BP27832).

Healthy Volunteer Clinical Trial

Hoffmann-La Roche - Recruiting 18 years to 65 years.
- MULTI-CENTER COGNITION ASSESSMENT IN HEALTHY SUBJECTS TO COLLECT REFERENCE DATA FOR COMPARISON TO PATIENTS WITH DEPRESSION.

Rheumatoid Arthritis Clinical Trial using tocilizumab [RoActemra/Actemra]; DMARDs; corticosteroids

Hoffmann-La Roche - Recruiting 18 years or older.
- Open-label, Phase IIIb Study to Evaluate the Efficacy and Safety of Subcutaneous (SC) Tocilizumab Monotherapy or Combination Therapy With Methotrexate (MTX) or Other Non-biologic Disease Modifying Anti-rheumatic Drugs (DMARDs) in Patients With Severe Rheumatoid Arthritis (RA) Who Are Being Treated With an Anti-tumour Necrosis Factor (Anti-TNF) Agent and That Have Not Achieved an Adequate Response to Treatment.
tocilizumab [RoActemra/Actemra]; DMARDs; corticosteroids

Sarcoma Clinical Trial using bevacizumab [Avastin]; Standard chemotherapy

Hoffmann-La Roche - Recruiting 6 Months to 18 years.
- An Open-label, Multi-center, Randomized Study of the Safety and Effect on Event-free Survival of Bevacizumab in Combination With Standard Chemotherapy in Childhood and Adolescent Patients With Metastatic Rhabdomyosarcoma and Non-rhabdomyosarcoma Soft Tissue Sarcoma.
bevacizumab [Avastin]; Standard chemotherapy

Anemia Clinical Trial using methoxy polyethylene glycol-epoetin beta [Mircera]

Hoffmann-La Roche - Recruiting 5 years to 17 years.
- An Open Label Multi-center, Multiple Dose Study to Determine the Optimum Starting Dose of Intravenous MIRCERA for Maintenance Treatment of Anemia in Pediatric Patients With Chronic Kidney Disease on Dialysis..
methoxy polyethylene glycol-epoetin beta [Mircera]

Non-Hodgkin's Lymphoma Clinical Trial using Mabthera intravenous; MabThera subcutaneous

Hoffmann-La Roche - Recruiting 18 years or older.
- A Two-stage Phase III, International, Multi-center, Randomized, Controlled, Open-label Study to Investigate the Pharmacokinetics, Efficacy and Safety of Rituximab SC in Combination With CHOP or CVP Versus Rituximab IV in Combination With CHOP or CVP in Patients With Previously Untreated Follicular Lymphoma Followed by Maintenance Treatment With Either Rituximab SC or Rituximab IV.
Mabthera intravenous; MabThera subcutaneous

Non-Hodgkin's Lymphoma Clinical Trial using rituximab [MabThera/Rituxan]; chemotherapy

Hoffmann-La Roche - Recruiting 18 years or older.
- .
rituximab [MabThera/Rituxan]; chemotherapy

Multiple Myeloma, Neoplasms Clinical Trial using Vemurafenib

Hoffmann-La Roche - Recruiting 18 years or older.
- An Open-label, Phase II Study of Vemurafenib in Patients With BRAF V600 Mutation-positive Cancers.
Vemurafenib

Breast Cancer Clinical Trial using trastuzumab [Herceptin]; paclitaxel; docetaxel

Hoffmann-La Roche - Recruiting 18 years or older.
- A Multicenter, Single Arm, Open-Label PhIV Study to Investigate the Effect of First-Line Herceptin (Trastuzumab) in Combination With a Taxane in Patients With Metastatic Breast Cancer Who Relapsed After Receiving (Neo)Adjuvant Herceptin for HER2-Positive Early Breast Cancer.
trastuzumab [Herceptin]; paclitaxel; docetaxel

Cytomegalovirus Infections, Transplantation Clinical Trial

Hoffmann-La Roche - Recruiting 20 years to 50 years.
- A Multicenter Prospective Cohort Study to Investigate if Ganciclovir Significantly Affects Spermatogenesis in Adult Male Renal Transplant Recipients Receiving up to 200 Days Valganciclovir vs. Concurrent Untreated Matched Controls.

Basal Cell Carcinoma Clinical Trial using vismodegib; placebo

Hoffmann-La Roche - Recruiting 18 years or older.
- A Randomized, Double-blinded, Regimen-controlled, Phase II, Multicenter Study to Assess the Efficacy and Safety of Two Different Vismodegib Regimens in Patients With Multiple Basal Cell Carcinomas.
vismodegib; placebo

Lymphoma, B-Cell Clinical Trial using RO5072759; rituximab [MabThera/Rituxan]; CHOP chemotherapy

Hoffmann-La Roche - Recruiting 18 years or older.
- A Phase III, Multicenter, Open-label Randomized Trial Comparing the Efficacy of GA101 (RO5072759) in Combination With CHOP (G-CHOP) Versus Rituximab and CHOP (R-CHOP) in Previously Untreated Patients With CD20-positive Diffuse Large B-cell Lymphoma (DLBCL).
RO5072759; rituximab [MabThera/Rituxan]; CHOP chemotherapy

Non-Small Cell Lung Cancer Clinical Trial using erlotinib [Tarceva]; Placebo

Hoffmann-La Roche - Recruiting 18 years or older.
- A Randomized, Double-blind, Placebo-controlled Phase 3 Study of First-line Maintenance Tarceva vs Tarceva at the Time of Disease Progression in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Who Have Not Progressed Following 4 Cycles of Platinum-based Chemotherapy.
erlotinib [Tarceva]; Placebo

Juvenile Idiopathic Arthritis, Rheumatoid Arthritis Clinical Trial using Tocilizumab [RoActemra/Actemra]

Hoffmann-La Roche - Recruiting N/A to 24 Months.
- A Phase I Pharmacokinetic and Safety Study of Tocilizumab (TCZ) in Patients Less Than 2 Years Old With Active Systemic Juvenile Idiopathic Arthritis (sJIA).
Tocilizumab [RoActemra/Actemra]

Breast Cancer Clinical Trial using trastuzumab [Herceptin]

Hoffmann-La Roche - Recruiting 18 years or older.
- A PHASE III PROSPECTIVE, TWO-COHORT NON-RANDOMIZED, MULTI-CENTRE, MULTINATIONAL, OPEN LABEL STUDY TO ASSESS THE SAFETY OF ASSISTED- AND SELF-ADMINISTERED SUBCUTANEOUS TRASTUZUMAB AS THERAPY IN PATIENTS WITH OPERABLE HER2-POSITIVE EARLY BREAST CANCER [SafeHer Study].
trastuzumab [Herceptin]

Hepatitis C, Chronic Clinical Trial

Hoffmann-La Roche - Recruiting 18 years or older.
- Multi-Center, Non-Interventional Study, on the Efficacy of Dual and Triple Therapies Based on Pegylated Interferon Alfa-2a for the Treatment of Chronic Hepatitis C Patients.

Breast Cancer Clinical Trial using Kadcyla (trastuzumab emtansine)

Hoffmann-La Roche - Recruiting 18 years or older.
- A Two-cohort, Open-label, Multicenter Study of Trastuzumab Emtansine (T-DM1) in HER2-positive Locally Advanced or Metastatic Breast Cancer Patients Who Have Received Prior Anti-HER2 and Chemotherapy-based Treatment..
Kadcyla (trastuzumab emtansine)

Rheumatoid Arthritis Clinical Trial using tocilizumab [RoActemra/Actemra]

Hoffmann-La Roche - Recruiting 18 years or older.
- A Multicenter, Open-Label, Single-Arm Extension Study To Describe The Safety Of Tocilizumab Treatment In Brazilian Patients With DMARDs Refractory Rheumatoid Arthritis Which Completed Studies ML21530 And MA21488 And Presenting An Indication Of Maintaining The Tocilizumab Treatment.
tocilizumab [RoActemra/Actemra]

Lymphoma, B-Cell, Non-Hodgkin's Lymphoma Clinical Trial using rituximab [MabThera/Rituxan]; CHOP; CVP; bendamustine

Hoffmann-La Roche - Recruiting 18 years to 80 years.
- A Randomized, Open-label, Multicenter Study to Evaluate Patient Preference With Subcutaneous Administration of Rituximab Versus Intravenous Rituximab in Previously Untreated Patients With CD20+ Diffuse Large B-cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1, 2 or 3a.
rituximab [MabThera/Rituxan]; CHOP; CVP; bendamustine

Non-Small Cell Lung Cancer Clinical Trial using RO5452802; erlotinib [Tarceva]

Hoffmann-La Roche - Recruiting 18 years or older.
- AN OPEN-LABEL, NON-RANDOMIZED, MULTICENTER PHASE I/II TRIAL OF RO5424802 GIVEN ORALLY TO NON - SMALL CELL LUNG CANCER PATIENTS WHO HAVE ALK MUTATION AND FAILED CRIZOTINIB TREATMENT.
RO5452802; erlotinib [Tarceva]

Asthma Clinical Trial using lebrikizumab; placebo

Hoffmann-La Roche - Recruiting 18 years to 75 years.
- A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lebrikizumab in Patients With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and a Second Controller Medication.
lebrikizumab; placebo

Healthy Volunteer Clinical Trial using RO6870868; placebo

Hoffmann-La Roche - Recruiting 18 years to 65 years.
- A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study in Healthy Volunteers to Assess the Safety, Tolerability, Pharmacodynamics and the Effect of Food on the Pharmacokinetics of RO6870868.
RO6870868; placebo

Asthma Clinical Trial using corticosteroids; prednisolone; LABA

Hoffmann-La Roche - Recruiting 12 years to 75 years.
- A STUDY TO MEASURE SERUM PERIOSTIN, ASTHMA-RELATED BIOMARKERS AND RESPONSE TO PREDNISOLONE IN ADULT AND ADOLESCENT PATIENTS WITH SEVERE ORAL CORTICOSTEROID-DEPENDENT ASTHMA.
corticosteroids; prednisolone; LABA

Breast Cancer Clinical Trial using trastuzumab [Herceptin]; paclitaxel; docetaxel; carboplatin; chemotherapy

Hoffmann-La Roche - Recruiting 18 years or older.
- AN OPEN-LABEL, MULTINATIONAL, MULTICENTER, PHASE IIIB STUDY WITH SUBCUTANEOUS ADMINISTRATION OF TRASTUZUMAB IN PATIENTS WITH HER2-POSITIVE EARLY BREAST CANCER TO EVALUATE PATIENT SATISFACTION.
trastuzumab [Herceptin]; paclitaxel; docetaxel; carboplatin; chemotherapy

Breast Cancer Clinical Trial using trastuzumab emtansine [Kadcyla]; trastuzumab [Herceptin]; pertuzumab [Perjeta]; taxane; anthracycline-based chemotherapy

Hoffmann-La Roche - Recruiting 18 years or older.
- A RANDOMIZED, MULTICENTER, OPEN-LABEL, PHASE III TRIAL COMPARING TRASTUZUMAB PLUS PERTUZUMAB PLUS A TAXANE FOLLOWING ANTHRACYCLINES VERSUS TRASTUZUMAB EMTANSINE PLUS PERTUZUMAB FOLLOWING ANTHRACYCLINES AS ADJUVANT THERAPY IN PATIENTS WITH OPERABLE HER2?POSITIVE PRIMARY BREAST CANCER.
trastuzumab emtansine [Kadcyla]; trastuzumab [Herceptin]; pertuzumab [Perjeta]; taxane; anthracycline-based chemotherapy

Non-Small Cell Lung Cancer Clinical Trial

Hoffmann-La Roche - Recruiting 18 years or older.
- THE SURVIVAL OF NON SMALL CELL LUNG CARCINOMA EGFR NON-MUTATED (WILD TYPE) PATIENTS TREATED WITH ERLOTINIB (TARCEVA) AFTER THE FAILURE OF AT LEAST ONE CHEMOTHERAPY REGIMEN..

Chronic Lymphocytic Leukemia Clinical Trial using GDC-0199; Rituximab [MabThera/Rituxan]; Bendamustine

Hoffmann-La Roche - Recruiting 18 years or older.
- A MULTICENTER, PHASE III, OPEN-LABEL, RANDOMIZED STUDY IN RELAPSED/REFRACTORY PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA TO EVALUATE THE BENEFIT OF GDC-0199 (ABT-199) PLUS RITUXIMAB COMPARED WITH BENDAMUSTINE PLUS RITUXIMAB.
GDC-0199; Rituximab [MabThera/Rituxan]; Bendamustine

Rheumatoid Arthritis Clinical Trial using tocilizumab [RoActemra/Actemra]

Hoffmann-La Roche - Recruiting 18 years or older.
- An Open-label, Single Arm Study to Evaluate the Efficacy and Safety and Tolerability of Tocilizumab (TCZ) Subcutaneous in TCZ-na‹ve Patients With Active Rheumatoid Arthritis.
tocilizumab [RoActemra/Actemra]

Neoplasms Clinical Trial using 4 mg/kg Onartuzumab (MetMAb); 15 mg/kg Onartuzumab (MetMAb); 30 mg/kg Onartuzumab (MetMAb)

Hoffmann-La Roche - Recruiting 18 years or older.
- A PHASE I STUDY OF THE PHARMACOKINETICS AND SAFETY OF ONARTUZUMAB IN CHINESE PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS.
4 mg/kg Onartuzumab (MetMAb); 15 mg/kg Onartuzumab (MetMAb); 30 mg/kg Onartuzumab (MetMAb)

Anemia Clinical Trial using methoxy polyethylene glycol-epoetin beta [Mircera]; ESAs (darbepoetin alfa, epoetin alfa or epoetin beta)

Hoffmann-La Roche - Recruiting 18 years or older.
- A Randomized, Open Label Study to Assess All-cause Mortality and Cardiovascular Morbidity in Patients With Chronic Kidney Disease on Dialysis and Those Not on Renal Replacement Therapy Under Treatment With Mircera or Reference ESAs..
methoxy polyethylene glycol-epoetin beta [Mircera]; ESAs (darbepoetin alfa, epoetin alfa or epoetin beta)

Anemia Clinical Trial using methoxy polyethylene glycol-epoetin beta [Mircera]

Hoffmann-La Roche - Recruiting 18 years or older.
- A Single Arm Open Label Multicenter Interventional Study to Assess the Efficacy, Safety, and Tolerability of Every 4 Weeks Administration of Subcutaneous C.E.R.A. for the Treatment of Chronic Renal Anaemia in Diabetic Nephropathy With CKD Stages III-IV Not on Dialysis, Not Currently Treated With ESA..
methoxy polyethylene glycol-epoetin beta [Mircera]

Lymphocytic Leukemia, Chronic Clinical Trial

Hoffmann-La Roche - Recruiting 18 years or older.
- An Observational Phase IV Non Interventional Study Evaluating Further the Safety of Rituximab in Combination With Various Chemotherapies for the Treatment of Patients With CD20- Positive B-cell Chronic Lymphocytic Leukaemia in Greece.

Malignant Melanoma, Neoplasms Clinical Trial using vemurafenib; rifampin

Hoffmann-La Roche - Recruiting 18 years or older.
- A Phase I, Open-Label, Multicenter, Three-Period, One-Sequence Study To Investigate The Effect Of Rifampin On The Pharmacokinetics Of A Single Oral Dose Of 960 Mg Of Vemurafenib.
vemurafenib; rifampin

Colorectal Cancer Clinical Trial

Hoffmann-La Roche - Recruiting 18 years or older.
- A Non-interventional Multicenter Study of First-line Avastinr (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer.

Neoplasms Clinical Trial using bevacizumab [Avastin]

Hoffmann-La Roche - Recruiting 18 years or older.
- An Open Label Multicentre Extension Study of Bevacizumab Administered as Single Agent or in Combination With Other Anticancer Therapies in Patients on Study Treatment With Bevacizumab at the End of a F. Hoffmann-La Roche and/or Genentech Sponsored Study.
bevacizumab [Avastin]

Alzheimer Disease Clinical Trial using RO4602522; RO4601522; placebo; donepezil; rivastigmine; galantamine; memantine

Hoffmann-La Roche - Recruiting 50 years to 90 years.
- A PHASE II, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RO4602522 ADDED TO BACKGROUND ALZHEIMER'S DISEASE THERAPY IN PATIENTS WITH MODERATE SEVERITY ALZHEIMER'S DISEASE.
RO4602522; RO4601522; placebo; donepezil; rivastigmine; galantamine; memantine

Hepatitis C, Chronic Clinical Trial

Hoffmann-La Roche - Recruiting 18 years or older.
- A Roche Project in Cooperation With the Bng (Association of German Resident Gastroenterologists) for Quality Assurance in the Dual- or Triple-therapy of Chronic Hepatitis C With Peg-(40kd)-Interferon Alfa 2a (Pegasys) at Hepatology Centers.

Rheumatoid Arthritis Clinical Trial

Hoffmann-La Roche - Recruiting 18 years or older.
- A Multi-national, Multi-center Non-interventional Study in Rheumatoid Arthritis (RA) Patients Treated With Tocilizumab.

Non-Small Cell Lung Cancer Clinical Trial using erlotinib [Tarceva]; Placebo; Onartuzumab [MetMAb]

Hoffmann-La Roche - Recruiting 18 years or older.
- A RANDOMIZED, PHASE III, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ONARTUZUMAB (MetMAb) IN COMBINATION WITH ERLOTINIB AS SECOND- OR THIRD-LINE TREATMENT FOR PATIENTS WITH MET-POSITIVE INCURABLE STAGE IIIB/IV NON-SMALL CELL LUNG CANCER.
erlotinib [Tarceva]; Placebo; Onartuzumab [MetMAb]

Hepatitis B, Chronic Clinical Trial using peginterferon alfa-2a [Pegasys]; nucleos(t)ide analogues

Hoffmann-La Roche - Recruiting 18 years to 65 years.
- A Phase IIb, Open Label, Single Arm, Multicenter Study to Evaluate the Effect of 48-weeks PEG-Interferon Alfa-2a (PEG-IFN) Administration on Serum HBsAg in Chronic Hepatitis B, HBeAg-Negative, Genotype D Patients on Treatment With Nucleos(t)Ide Analogues (NAs), Showing Stable HBV DNA Suppression.
peginterferon alfa-2a [Pegasys]; nucleos(t)ide analogues

Healthy Volunteer Clinical Trial using RO5545965; placebo

Hoffmann-La Roche - Recruiting 18 years to 64 years.
- A Single-Center, Randomized, Investigator/Subject-Blind, Adaptive Multiple Ascending-Dose, Placebo-Controlled, Parallel Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO5545965 Following Oral Administration in Healthy Subjects..
RO5545965; placebo

Rheumatoid Arthritis Clinical Trial

Hoffmann-La Roche - Recruiting 18 years or older.
- Tocilizumab (RoActemra) poST Marketing Observational Study in DMARD-IR Patients to Assess Efficacy and Safety in routiNE Clinical Practice - STONE.

Glioblastoma Clinical Trial using bevacizumab [Avastin]; temozolomide; Radiotherapy; placebo; SOC

Hoffmann-La Roche - Recruiting 18 years or older.
- A Double-blind, Placebo-controlled, Randomized, Phase IIIb Trial Evaluating the Efficacy and Safety of Standard of Care (SOC) +/- Continuous Bevacizumab Treatment Following Progression of Disease (PD) in Patients With Glioblastoma (GBM) After First (1st)-Line Treatment With Radiotherapy, Temozolomide and Bevacizumab.
bevacizumab [Avastin]; temozolomide; Radiotherapy; placebo; SOC

Malignant Melanoma Clinical Trial using vemurafenib; Placebo; GDC-0973 (cobimetinib)

Hoffmann-La Roche - Recruiting 18 years or older.
- A PHASE III, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF VEMURAFENIB VERSUS VEMURAFENIB PLUS GDC-0973 (COBIMETINIB) IN PREVIOUSLY UNTREATED BRAFV600-MUTATION POSITIVE PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA.
vemurafenib; Placebo; GDC-0973 (cobimetinib)

Rheumatoid Arthritis Clinical Trial using tocilizumab [RoActemra/Actemra]; methotrexate; placebo

Hoffmann-La Roche - Recruiting 18 years or older.
- A RANDOMIZED, DOUBLE-BLIND TRIAL ASSESSING THE IMPACT OF METHOTREXATE DISCONTINUATION ON THE EFFICACY OF SUBCUTANEOUS TOCILIZUMAB WITH METHOTREXATE THERAPY.
tocilizumab [RoActemra/Actemra]; methotrexate; placebo

Rheumatoid Arthritis Clinical Trial using tocilizumab [RoActemra/Actemra]

Hoffmann-La Roche - Recruiting 18 years or older.
- Multi-center, Open-label Single Arm Phase IIIb Study on Safety and Efficacy of Subcutaneous (SC) Tocilizumab in Monotherapy or in Combination With Methotrexate (MTX) or Other Non-biologic Disease Modifying Antirheumatic Drugs (DMARDs) in Rheumatoid Arthritis Patients With an Inadequate Response to Non-biologic DMARDs.
tocilizumab [RoActemra/Actemra]

Rheumatoid Arthritis Clinical Trial using tocilizumab [RoActemra/Actemra]; methotrexate; DMARD

Hoffmann-La Roche - Recruiting 18 years or older.
- A PHASE IIIb STUDY TO EVALUATE THE EFFICACY, SAFETY AND TOLERABILITY OF SUBCUTANEOUS (SC) TOCILIZUMAB (TCZ) GIVEN AS MONOTHERAPY OR IN COMBINATION WITH METHOTREXATE (MTX) OR OTHER NON BIOLOGICS DMARDs IN SUBJECTS WITH RHEUMATOID ARTHRITIS.
tocilizumab [RoActemra/Actemra]; methotrexate; DMARD

Non-Small Cell Lung Cancer Clinical Trial using Erlotinib [Tarceva]; gemcitabine; cisplatin

Hoffmann-La Roche - Recruiting 18 years or older.
- ENSURE Extension Study to Assess the PFS of First-Line Erlotinib (Tarceva) and Erlotinib After Disease Progression in Chinese Population Enrolled in the ENSURE Trial.
Erlotinib [Tarceva]; gemcitabine; cisplatin

Alzheimer Disease Clinical Trial using gantenerumab; placebo

Hoffmann-La Roche - Recruiting 50 years to 90 years.
- A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER, EFFICACY AND SAFETY STUDY OF GANTENERUMAB IN PATIENTS WITH MILD ALZHEIMER'S DISEASE.
gantenerumab; placebo

Neoplasms Clinical Trial using vemurafenib

Hoffmann-La Roche - Recruiting 18 years or older.
- A Phase IV, PostMarketing, Open-Label, Extension (Rollover) Study of Vemurafenib in Patients With BRAF V600 Mutation-Positive Malignancies Previously Enrolled in an Antecedent Vemurafenib Protocol.
vemurafenib

Colorectal Cancer Clinical Trial

Hoffmann-La Roche - Recruiting 18 years or older.
- Non-interventional Study of Avastinr First-line in Metastatic Colorectal Cancer (Koralle).

Basal Cell Carcinoma Clinical Trial using vismodegib

Hoffmann-La Roche - Recruiting 18 years or older.
- A Single Arm, Open-label, Phase II, Multicentre Study, to Assess the Safety of Vismodegib (GDC-0449) in Patient With Locally Advanced or Metastatic Basal Cell Carcinoma (BCC).
vismodegib

Breast Cancer Clinical Trial using pertuzumab; placebo; trastuzumab [Herceptin]; Chemotherapy

Hoffmann-La Roche - Recruiting 18 years or older.
- A Randomized Multicenter, Double-blind, Placebo-controlled Comparison of Chemotherapy Plus Trastuzumab Plus Placebo Versus Chemotherapy Plus Trastuzumab Plus Pertuzumab as Adjuvant Therapy in Patients With Operable HER2-positive Primary Breast Cancer.
pertuzumab; placebo; trastuzumab [Herceptin]; Chemotherapy

Breast Cancer, Colorectal Cancer, Gastric Cancer, Malignant Melan Clinical Trial

Hoffmann-La Roche - Recruiting 18 years or older.
- OCCURRENCE RATE OF COLON CANCER, BREAST CANCER, GASTRIC CANCER AND MALIGNANT MELANOMA IN TURKEY & DIAGNOSIS AND TREATMENT CHARACTERISTICS.

Malignant Melanoma, Neoplasms Clinical Trial using vemurafenib; tizanidine

Hoffmann-La Roche - Recruiting 18 years to 70 years.
- A PHASE I, OPEN-LABEL, MULTICENTER, 3- PERIOD, FIXED-SEQUENCE STUDY TO INVESTIGATE THE EFFECT OF VEMURAFENIB ON THE PHARMACOKINETICS OF SINGLE DOSE OF TIZANIDINE (A CYP1A2 SUBSTRATE) IN PATIENTS WITH BRAFV600 MUTATION-POSITIVE METASTATIC MALIGNANCY.
vemurafenib; tizanidine

Malignant Melanoma, Neoplasms Clinical Trial using vemurafenib; acenocoumarol

Hoffmann-La Roche - Recruiting 18 years to 70 years.
- A PHASE I, OPEN-LABEL, MULTICENTER, 3-PERIOD, FIXED-SEQUENCE STUDY TO INVESTIGATE THE EFFECT OF VEMURAFENIB ON THE PHARMACOKINETICS OF A SINGLE ORAL DOSE OF ACENOCOUMAROL IN PATIENTS WITH BRAFV600 MUTATION-POSITIVE METASTATIC MALIGNANCY.
vemurafenib; acenocoumarol

Glioma Clinical Trial using temozolomide (TMZ); bevacizumab [Avastin]; Radiotherapy

Hoffmann-La Roche - Recruiting 6 Months to 18 years.
- A Phase II Open-Label, Randomized, Multi-Centre Comparative Study Of Bevacizumab-Based Therapy In Paediatric Patients With Newly Diagnosed Supratentorial, Infratentorial Cerebellar, Or Peduncular High-Grade Glioma.
temozolomide (TMZ); bevacizumab [Avastin]; Radiotherapy